艾塞那肽在中青年2型糖尿病合并非酒精性脂肪肝治疗中的作用及对患者各项指标的影响

摘要

目的:观察艾塞那肽在中青年2型糖尿病合并非酒精性脂肪肝治疗中的作用,及对患者体质量、血糖、血脂、胰岛素抵抗及脂肪肝病变程度的影响.方法:口服降糖药治疗不达标的中青年2型糖尿病合并非酒精性脂肪肝患者70例随机分为两组,每组35例.观察组在原降糖方案基础上加用艾塞那肽,对照组在原方案基础上加用精蛋白生物合成人胰岛素注射液,干预时间3个月.比较患者治疗前后的体质量、体质指数(BMI)、腰围、胰岛素抵抗指数 ( HOMA-IR)、空腹血糖 ( FPG)、餐后2 h血糖 (2hPG)、糖化血红蛋白 (HbA1c)、血脂(TG、TC、LDL-C、HDL-C)、肝功能指标 (ALT、AST、GGT), 及脂肪肝治疗疗效.结果:治疗3个月后,观察组的血糖控制与对照组无显著差异(P>0. 05).但观察组患者的体质量、BMI、腰围、HOMA-IR、TG、ALT、AST、GGT均较治疗前显著下降 (P0. 05).观察组治疗脂肪肝的总有效率显著高于对照组 (P0. 05). The total efficiency for treating NAFLD in observation group was significantly higher than that in the control group (P<0. 05). Conclusion: Besides reducing blood glucose effectively, exenatide can also obviously reduce body weight and TG level, improve insulin resistance, decrease liver en-zymes, and significantly ameliorate the degree of fatty liver. The results suggested that exenatide might be a new therapeutic option for young and middle-aged patients with type 2 diabetes and NAFLD.